

# Martin Schreiber

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7709021/publications.pdf>

Version: 2024-02-01

51  
papers

5,355  
citations

212478

28  
h-index

223390

49  
g-index

53  
all docs

53  
docs citations

53  
times ranked

8743  
citing authors

#	ARTICLE	IF	CITATIONS
1	Discrimination between 34 of 36 Possible Combinations of Three C>T SNP Genotypes in the MGMT Promoter by High Resolution Melting Analysis Coupled with Pyrosequencing Using A Single Primer Set. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12527.	1.8	2
2	The 40bp Indel Polymorphism rs150550023 in the MDM2 Promoter is Associated with Intriguing Shifts in Gene Expression in the p53-MDM2 Regulatory Hub. <i>Cancers</i> , 2020, 12, 3363.	1.7	3
3	Association of the MDM2 SNP285 and SNP309 Genetic Variants with the Risk, Age at Onset and Prognosis of Breast Cancer in Central European Women: A Hospital-Based Case-Control Study. <i>International Journal of Molecular Sciences</i> , 2019, 20, 509.	1.8	11
4	Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer. <i>Hormones and Cancer</i> , 2018, 9, 128-138.	4.9	19
5	Differential prognostic impact of interleukin-34 mRNA expression and infiltrating immune cell composition in intrinsic breast cancer subtypes. <i>Oncotarget</i> , 2018, 9, 23126-23148.	0.8	32
6	More is not always better: clinical genetics of familial breast cancer in the era of massively enhanced sequencing capacities. <i>Translational Cancer Research</i> , 2016, 5, S387-S391.	0.4	1
7	Association of the rs1346044 Polymorphism of the Werner Syndrome Gene RECQL2 with Increased Risk and Premature Onset of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2015, 16, 29643-29653.	1.8	11
8	Potential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkers. <i>British Journal of Cancer</i> , 2015, 113, 1035-1045.	2.9	25
9	AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis. <i>Oncotarget</i> , 2015, 6, 20697-20710.	0.8	35
10	New approaches for breast cancer: should Ret kinase be considered as a novel therapeutic target?. <i>Future Oncology</i> , 2014, 10, 333-336.	1.1	1
11	Analysis of the rs10046 Polymorphism of Aromatase (CYP19) in Premenopausal Onset of Human Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2014, 15, 712-724.	1.8	19
12	Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogenâ€“urokinase plasminogen activator receptor systemâ€“regulated secretion during breast cancer progression. <i>Breast Cancer Research</i> , 2014, 16, 433.	2.2	20
13	Polymorphisms of VEGF and VEGF receptors are associated with the occurrence of ovarian hyperstimulation syndrome (OHSS)â€“a retrospective caseâ€“control study. <i>Journal of Ovarian Research</i> , 2014, 7, 54.	1.3	20
14	Association of the G473A Polymorphism and Expression of Lysyl Oxidase with Breast Cancer Risk and Survival in European Women: A Hospital-Based Case-Control Study. <i>PLoS ONE</i> , 2014, 9, e105579.	1.1	15
15	The L10P Polymorphism and Serum Levels of Transforming Growth Factor Î²1 in Human Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 15376-15385.	1.8	24
16	Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells. <i>EMBO Molecular Medicine</i> , 2013, 5, 1335-1350.	3.3	80
17	The Pro Allele of the p53 Codon 72 Polymorphism Is Associated with Decreased Intratumoral Expression of BAX and p21, and Increased Breast Cancer Risk. <i>PLoS ONE</i> , 2012, 7, e47325.	1.1	38
18	Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. <i>Journal of Clinical Investigation</i> , 2011, 121, 2000-2012.	3.9	163

#	ARTICLE	IF	CITATIONS
19	Annexin A1 attenuates EMT and metastatic potential in breast cancer. <i>EMBO Molecular Medicine</i> , 2010, 2, 401-414.	3.3	71
20	Prognostic relevance of hypoxia inducible factor-1 $\alpha$ expression in patients with melanoma. <i>Clinical and Experimental Dermatology</i> , 2009, 34, e962-e964.	0.6	30
21	<i>Entamoeba histolytica</i> : Response of the parasite to metronidazole challenge on the levels of mRNA and protein expression. <i>Experimental Parasitology</i> , 2008, 120, 403-410.	0.5	19
22	Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells. <i>Carcinogenesis</i> , 2007, 28, 49-59.	1.3	64
23	The transcription factor ZEB1 ( $\Delta$ EF1) represses Plakophilin 3 during human cancer progression. <i>FEBS Letters</i> , 2007, 581, 1617-1624.	1.3	83
24	Regulation of dendritic cell differentiation and subset distribution by the zinc finger protein CTCF. <i>Immunology Letters</i> , 2007, 109, 165-174.	1.1	11
25	The transcription factor ZEB1 ( $\Delta$ EF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity. <i>Oncogene</i> , 2007, 26, 6979-6988.	2.6	541
26	Can osteoclasts be excluded? (Reply). <i>Nature</i> , 2007, 445, E19-E20.	13.7	5
27	SNEV overexpression extends the life span of human endothelial cells. <i>Experimental Cell Research</i> , 2006, 312, 746-759.	1.2	60
28	Regulation of cancer cell migration and bone metastasis by RANKL. <i>Nature</i> , 2006, 440, 692-696.	13.7	709
29	IL6: A cytokine essential for EMT, tumor formation, and late events in metastasis in epithelial cells. <i>Cancer Cell</i> , 2006, 10, 227-239.	7.7	161
30	Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/ MALDI-TOF/TOF and data validation by routine clinical assays. <i>Electrophoresis</i> , 2006, 27, 1641-1650.	1.3	121
31	1 Identification of Tumor-Specific Genes. <i>Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas</i> , 2005, , 3-21.	0.0	1
32	DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells. <i>Oncogene</i> , 2005, 24, 2375-2385.	2.6	697
33	Enrichment of low-abundant serum proteins by albumin/immunoglobulin G immunoaffinity depletion under partly denaturing conditions. <i>Electrophoresis</i> , 2005, 26, 2843-2849.	1.3	51
34	Expression of HER2 and the Coamplified Genes GRB7 and MLN64 in Human Breast Cancer: Quantitative Real-time Reverse Transcription-PCR as a Diagnostic Alternative to Immunohistochemistry and Fluorescence In situ Hybridization. <i>Clinical Cancer Research</i> , 2005, 11, 8348-8357.	3.2	97
35	Genome-wide expression profiling of microdissected human breast tumor cells: tumor classification predictive of metastases and clinical outcome. <i>Breast Cancer Research</i> , 2005, 7, 1.	2.2	0
36	Tissue-Wide Expression Profiling Using cDNA Subtraction and Microarrays to Identify Tumor-Specific Genes. <i>Cancer Research</i> , 2004, 64, 844-856.	0.4	211

#	ARTICLE	IF	CITATIONS
37	Insulin-Like Growth Factor (IGF)-I and IGF-II Serum Concentrations in Patients with Benign and Malignant Breast Lesions. <i>Clinical Cancer Research</i> , 2004, 10, 4003-4009.	3.2	32
38	MKK7 couples stress signalling to G2/M cell-cycle progression and cellular senescence. <i>Nature Cell Biology</i> , 2004, 6, 215-226.	4.6	134
39	Use of High-Throughput Protein Array for Profiling of Differentially Expressed Proteins in Normal and Malignant Breast Tissue. <i>Breast Cancer Research and Treatment</i> , 2004, 86, 283-293.	1.1	92
40	The mouse mammary tumor virus-like env gene sequence is not detectable in breast cancer tissue of Austrian patients. <i>Oncology Reports</i> , 2003, 10, 1025.	1.2	16
41	Pharmacological modulation of IGF serum concentrations as a therapeutic approach to control the growth of malignant breast tumors. <i>Drugs of Today</i> , 2003, 39, 115.	2.4	4
42	Interleukin-1 System and Sex Steroid Receptor Gene Expression in Human Endometrial Cancer. <i>Gynecologic Oncology</i> , 2002, 85, 423-430.	0.6	15
43	IGF-1 and IGF-2 serum concentrations in patients with benign and malignant breast cancer: Free IGF-2 is correlated with breast tumor size. <i>European Journal of Cancer</i> , 2002, 38, S54.	1.3	0
44	Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. <i>EMBO Journal</i> , 2001, 20, 1952-1962.	3.5	264
45	Key Regulatory Transcription Factors Involved in Placental Trophoblast Development—A Review. <i>Placenta</i> , 2001, 22, S83-S92.	0.7	45
46	Protective Role of Raf-1 in Salmonella-Induced Macrophage Apoptosis. <i>Journal of Experimental Medicine</i> , 2001, 193, 353-364.	4.2	59
47	c-Jun-Dependent CD95-L Expression Is a Rate-Limiting Step in the Induction of Apoptosis by Alkylating Agents. <i>Molecular and Cellular Biology</i> , 2000, 20, 575-582.	1.1	144
48	The Mammalian UV Response. <i>Cell</i> , 2000, 103, 897-908.	13.5	280
49	JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development. <i>Current Biology</i> , 1999, 9, 116-125.	1.8	288
50	Control of cell cycle progression by c-Jun is p53 dependent. <i>Genes and Development</i> , 1999, 13, 607-619.	2.7	493
51	Structure and chromosomal assignment of the mouse fra-1 gene, and its exclusion as a candidate gene for oc (osteosclerosis). <i>Oncogene</i> , 1997, 15, 1171-1178.	2.6	37